TRBV7-6: A Potential Drug Target for Neuronal and Tumor Cells

Target Name: TRBV7-6

NCBI ID: G28592

TRBV7-6

Other Name(s): TCRBV6S3A1N1T | TRBV76 | T cell receptor beta variable 7-6 | TCRBV7S6

TRBV7-6: A Potential Drug Target for Neuronal and Tumor Cells

TRBV7-6 (TCRBV6S3A1N1T) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the TRBV7 family, which includes several similar proteins that are involved in the development and maintenance of tissues, including the nervous system and blood vessels.

One of the unique features of TRBV7-6 is its ability to interact with several different proteins, including the T-cell receptor alpha chain (TCRBV7-伪). This interaction allows TRBV7-6 to regulate the activity of T cells, which are a type of immune cell that play a critical role in fighting off infections and diseases.

TRBV7-6 has also been shown to interact with several other proteins, including the protein p16INK4a. This interaction is of particular interest because p16INK4a is a known gene suppressor that can help to keep cells under control and prevent them from multiplying. By interacting with p16INK4a , TRBV7-6 may be able to regulate the growth and development of cancer cells.

In addition to its interactions with TCRBV7-伪 and p16INK4a, TRBV7-6 has also been shown to play a role in the regulation of cell death. This is important because apoptosis is a natural way of cell death that occurs in organisms. plays an important role in scavenging and regeneration. Many diseases, such as tumors, are associated with abnormal occurrence of apoptosis. By modulating the activity of TRBV7-6, the scientists explored a new therapeutic strategy that inhibits apoptosis by activating TRBV7-6.

In addition, TRBV7-6 is also related to neuronal apoptosis. Research shows that when neurons die, TRBV7-6 is involved. This provides important clues for studying the regulation of neuronal death.

In drug research and development, TRBV7-6 is a potential drug target. Scientists have discovered a compound called a "TRBV7-6 inhibitor" that inhibits the binding of TRBV7-6 to TCRBV7-伪 and p16INK4a. By blocking this binding, TRBV7-6 inhibitors can slow the growth of neurons and tumor cells. In addition, TRBV7-6 inhibitors can also inhibit apoptosis, providing new ideas for the treatment of these diseases.

In short, TRBV7-6 is a protein of important biological significance, and its research and application prospects are very broad. By further studying the biological functions and drug targets of TRBV7-6, scientists are expected to bring new hope for the treatment of various diseases.

Protein Name: T Cell Receptor Beta Variable 7-6

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV7-6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV7-6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets